Fourteen of the 16 patients with HER2 positive breast cancers received systemic HER2-targeted treatment and 14 of them received anti-HER2 tyrosine kinase inhibitors such as lapatinib and pyrotinib. Here, ERBB2 is linked to breast carcinoma.